TARGETED TRAILBLAZER

What this means for you

Not registered yet, but its 09 Sept 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99383499

Mark type

Stylized text

Filed

09 Sept 2025

Attorney of record

Christina M. Licursi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceuticals for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products and preparations for use in relation to oncology; pharmaceutical products and preparations for use in relation to ophthalmology; pharmaceutical products and preparations for use in relation to neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and prevention of respiratory disease; pharmaceutical products and preparations for the treatment and prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging for the prevention and treatment of cancer; pharmaceutical products and preparations for the treatment and prevention of renal disease; pharmaceutical products and preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and prevention of muscular skeletal disease
• Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; scientific research services; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services in the fields of in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical research and development in the field of oncology; medical research and development in the field of ophthalmology; medical research and development in the field of neurology; medical research and development in the field of anti-infective pharmaceuticals; medical research and development in the field of respiratory disease; medical research and development in the field of cardiovascular disease; medical research and development in the field of metabolic disease; medical research and development in the field of antiviral drugs; medical research and development in the field of diagnostics and imaging; medical research and development in the field of renal disease; medical research and development in the field of gastrointestinal disease; medical research and development in the field of muscular skeletal disease; pharmaceutical drug development services; pharmaceutical drug development services in the field of oncology; pharmaceutical drug development services in the field of ophthalmology; pharmaceutical drug development services in the field of neurology; pharmaceutical drug development services in the field of anti-infectives; pharmaceutical drug development services in connection with respiratory disease; pharmaceutical drug development services in connection with cardiovascular disease; pharmaceutical drug development services in connection with metabolic disease; pharmaceutical drug development services in connection with the treatment and prevention of viral infections; pharmaceutical drug development services in connection with diagnostics and imaging; pharmaceutical drug development services in connection with renal disease; pharmaceutical drug development services in connection with gastrointestinal disease; pharmaceutical drug development services in connection with muscular skeletal disease; information consultancy and advisory services relating to the aforesaid
• Class 044 — Medical, beauty and agricultural services: Medical services; medical testing services; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; medical and pharmaceutical consultancy and information services relating to pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid

Owner

• Bicycletx Limited, Cambridge, GB

Prosecution history

• 30 Mar 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 30 Mar 2026 — FINAL REFUSAL E-MAILED
• 30 Mar 2026 — FINAL REFUSAL WRITTEN
• 10 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 10 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 10 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 19 Dec 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 19 Dec 2025 — NON-FINAL ACTION E-MAILED
• 19 Dec 2025 — NON-FINAL ACTION WRITTEN
• 12 Dec 2025 — ASSIGNED TO EXAMINER
• 20 Nov 2025 — TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
• 20 Nov 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
• 09 Sept 2025 — APPLICATION FILING RECEIPT MAILED
• 09 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 09 Sept 2025 — NEW APPLICATION ENTERED